scispace - formally typeset
J

Jean-Jacques Body

Researcher at Université libre de Bruxelles

Publications -  397
Citations -  21506

Jean-Jacques Body is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 70, co-authored 384 publications receiving 19608 citations. Previous affiliations of Jean-Jacques Body include The Breast Cancer Research Foundation & University of California, San Francisco.

Papers
More filters
Journal ArticleDOI

A dose-finding study of zoledronate in hypercalcemic cancer patients.

Jean-Jacques Body, +4 more
- 01 Sep 1999 - 
TL;DR: An open‐label, dose‐finding, single‐dose phase I study in tumor‐induced hypercalcemia (TIH), which has been similarly used as a model to determine the active doses of other bisphosphonates, finding very low doses of zoledronate administered by a short‐time infusion effectively treated patients with TIH.
Journal ArticleDOI

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.

Pierre Bergmann, +8 more
- 01 Jan 2009 - 
TL;DR: To review the clinical value of bone turnover markers (BTM) and to initiate and/or monitor anti‐resorptive treatment for osteoporosis compared with bone mineral density (BMD).
Journal ArticleDOI

Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia

Jean-Jacques Body, +1 more
- 01 Mar 1992 - 
TL;DR: The urinary excretion of Pyr and D-Pyr was markedly increased in hypercalcemic cancer patients and was adequately lowered by bisphosphonate therapy, suggesting that these markers reflect different events of bone resorption.
Journal ArticleDOI

Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.

Jean-Pierre Devogelaer, +7 more
- 01 Jan 2006 - 
TL;DR: There is indeed no proof that the increased costs of combined treatments will translate into increased therapeutic efficacy, but there is an increasing body of evidence supporting the antifracture efficacy of bisphosphonates, notably alendronate and risedronate.
Journal ArticleDOI

Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS

Elena Tsourdi, +16 more
- 01 Jan 2021 - 
TL;DR: An updated systematic review of existing literature on changes of bone turnover, bone mineral density, and fracture risk after denosumab discontinuation provided advice on management based on expert opinion and indicated partial efficacy of subsequent antiresorptive treatment with results seemingly dependent on duration of denosUMab treatment.